Pfizer plans to stop enrollment in a study of its COVID-19 pill for patients with standard risk for developing severe disease after it failed to lower their risk of hospitalization or death.
The drugmaker said Tuesday (June 14) that it would stop adding new patients to the study testing Paxlovid in COVID-19 patients who were either unvaccinated or fully vaccinated with at least one medical condition that increased their risk of severe illness. The company said it will continue to evaluate the treatment in patients with high unmet need.
Last December, Pfizer reported early data from the study showing that Paxlovid didn’t reduce the risk of hospitalization or death in a way that was statistically significant.